Suppr超能文献

临床实践中使用劳拉西泮治疗躁动:一项系统评价。

Treatment of Agitation With Lorazepam in Clinical Practice: A Systematic Review.

作者信息

Amore Mario, D'Andrea Mariella, Fagiolini Andrea

机构信息

Section of Psychiatry, Department of Neuroscience, Ophthalmology, Genetics and Infant-Maternal Science, University of Genoa, Genoa, Italy.

Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico San Martino, Genoa, Italy.

出版信息

Front Psychiatry. 2021 Feb 22;12:628965. doi: 10.3389/fpsyt.2021.628965. eCollection 2021.

Abstract

Acute agitation is a frequent occurrence in both inpatient and outpatient psychiatric settings, and the use of medication to calm a patient may be warranted to mitigate the situation. Lorazepam is a benzodiazepine that is widely used for management of acute agitation. Despite its widespread use, there is remarkably little clinical evidence for the benefits of lorazepam in acute agitation. We performed a systematic review with focus on lorazepam, including all randomized clinical trials on lorazepam in mental and behavioral disorders, excluding studies on dementia and pediatric patients and in mixed conditions. A total of 11 studies met inclusion criteria, and all were in patients with mental and behavioral disorders. Most trials generally found improvements across a variety of outcomes related to agitation, although there was some disparity if specific outcomes were considered. In the five studies with haloperidol, the combination of lorazepam and haloperidol was superior to either agent alone, but with no differences between monotherapy with the individual agents. In the study comparing lorazepam to olanzapine, olanzapine was superior to lorazepam, and both were superior to placebo. As expected, the safety of lorazepam among the different studies was consistent with its well-characterized profile with dizziness, sedation, and somnolence being the most common adverse events. Based on this structured review, lorazepam can be considered to be a clinically effective means of treating the acutely agitated patient.

摘要

急性激越在住院和门诊精神科环境中都很常见,使用药物使患者镇静可能有助于缓解这种情况。劳拉西泮是一种苯二氮䓬类药物,广泛用于治疗急性激越。尽管其使用广泛,但关于劳拉西泮治疗急性激越的益处,临床证据却非常少。我们进行了一项以劳拉西泮为重点的系统评价,纳入了所有关于劳拉西泮治疗精神和行为障碍的随机临床试验,排除了关于痴呆患者、儿科患者以及混合情况的研究。共有11项研究符合纳入标准,且均为针对精神和行为障碍患者的研究。大多数试验总体上发现,与激越相关的各种结局都有所改善,不过如果考虑特定结局,则存在一些差异。在五项使用氟哌啶醇的研究中,劳拉西泮与氟哌啶醇联合使用优于单独使用任何一种药物,但两种药物单药治疗之间没有差异。在比较劳拉西泮与奥氮平的研究中,奥氮平优于劳拉西泮,且两者均优于安慰剂。正如预期的那样,不同研究中劳拉西泮的安全性与其已明确的特征相符,头晕、镇静和嗜睡是最常见的不良事件。基于这一结构化评价,劳拉西泮可被视为治疗急性激越患者的一种临床有效手段。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6d8/7937895/cb33938406cc/fpsyt-12-628965-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验